The DOI matches its Crossref record.
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
Open accessAbstract
Cancers, especially skin cancers, may develop in patients undergoing solid-organ transplantation who receive long-term immunosuppression. The use of anti–PD-1 in one such patient produced an antitumor response but led to rejection of the transplanted kidney.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
“However, several recent case reports have documented the risk of acute allograft rejection after anti-PD-1 therapy [85].”
BackgroundImmune checkpoint inhibitors in challenging populations
Johnson, D. B., Sullivan, R. J., & Menzies, A. M. (2017) · Cancer · doi:10.1002/cncr.30642 · Cited by 339
Abdel-Wahab, N., Safa, H., Abudayyeh, A., Johnson, D. H., Trinh, V. A., Zobniw, C. M., Lin, H., Wong, M. K., Abdelrahim, M., Gaber, A. O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0585-1 · Cited by 294
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
DeLeon, T. T., Salomao, M. A., Aqel, B. A., Sonbol, M. B., Yokoda, R. T., Ali, A. H., Moss, A. A., Mathur, A. K., Chascsa, D. M., Rakela, J., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.07.05 · Cited by 157
Immune Checkpoint Inhibitors in Organ Transplant Patients
Kittai, A. S., Oldham, H., Cetnar, J., & Taylor, M. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000180 · Cited by 151
Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab
Barnett, R., Barta, V. S., & Jhaveri, K. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1614298 · Cited by 136
Esfahani, K., Al-Aubodah, T.-A., Thebault, P., Lapointe, R., Hudson, M., Johnson, N. A., Baran, D., Bhulaiga, N., Takano, T., Cailhier, J.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12628-1 · Cited by 109
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
Ben Nasr, M., Usuelli, V., Dellepiane, S., Seelam, A. J., Fiorentino, T. V., D’Addio, F., Fiorina, E., Xu, C., Xie, Y., Balasubramanian, H. B., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.001 · Cited by 102
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?
De Bruyn, P., Van Gestel, D., Ost, P., Kruse, V., Brochez, L., Van Vlierberghe, H., Devresse, A., del Marmol, V., Le Moine, A., & Aspeslagh, S. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000505 · Cited by 79
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75
Aguirre, L. E., Guzman, M. E., Lopes, G., & Hurley, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0195 · Cited by 68
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67
Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy
Janowitz, T., Kleeman, S., & Vonderheide, R. H. (2021) · The Oncologist · doi:10.1002/onco.13680 · Cited by 42
Grant, M. J., DeVito, N., & Salama, A. K. S. (2018) · Melanoma Management · doi:10.2217/mmt-2018-0004 · Cited by 24
Sadaat, M., & Jang, S. (2018) · Journal of Oncology Practice · doi:10.1200/jop.2017.027326 · Cited by 23
Self-citation
Metadata
- Authors
- Lipson, E. J., Bagnasco, S. M., Moore, J., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-03
- Volume
- 374
- Issue
- 9
- Pages
- 896-898
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2303235652
- Cited by
- 278
- References
- 0
- FWCI
- 20.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
